The role of neurotrophic factors in the maintenance and survival of peripheral neuronal cells has been the subject of numerous studies. Administration of exogenous neurotrophic factors after nerve injury has been shown to mimic the effect of target organ-derived trophic factors on neuronal cells. After axotomy and during peripheral nerve regeneration, the neurotrophins NGF, NT-3 and BDNF show a well defined and selective beneficial effect on the survival and phenotypic expression of primary sensory neurons in dorsal root ganglia and of motoneurons in spinal cord. Other neurotrophic factors such as CNTF, GDNF and LIF also exert a variety of actions on neuronal cells, which appear to overlap and complement those of the neurotrophins. In addition, there is an indirect contribution of GGF to nerve regeneration. GGF is produced by neurons and stimulates proliferation of Schwann cells, underlining the close interaction between neuronal and glial cells during peripheral nerve regeneration. Different possibilities have been investigated for the delivery of growth factors to the injured neurons, in search of a suitable system for clinical applications. The studies reviewed in this article show the therapeutic potential of neurotrophic factors for the treatment of peripheral nerve injury and for neuropathies.
    
The process of nerve injury and regeneration involves many interactions between cellular elements and between these and the extracellular matrix. Immediately after axotomy, the proximal and distal nerve stumps retract, axoplasm leaks out and damaged membranes collapse. Macrophages are recruited to the site of the lesion during the first week postinjury (Perry et al. 1987) , contributing to lysis and phagocytosis of myelin and subsequent Schwann cell proliferation (Beuche & Friede, 1984) . Both cell types secrete mitogens and growth factors which play a role in axonal regeneration and remyelination (De Vries, 1993 ; Reynolds & Woolf, 1993) .
In the distal axonal stump, Wallerian degeneration takes place during the first few days postinjury. The axons degenerate, their myelin sheath detaches and Correspondence to Dr G. Terenghi, Blond McIndoe Laboratories, Department of Surgery, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2QG, UK. Tel. : j44 0171 794 0500, ext. 3944 ; e-mail : terenghi!mcindoe.ucl.demon.co.uk degrades, and the degradation products, together with macrophage secretion, stimulate the Schwann cells within the distal stump to proliferate within their basal lamina tubes De Vries, 1993) , forming the bands of Bu$ ngner . This proliferation continues for approximately 2 wk, with the Schwann cells forming a conduit which guides the regenerating axons to their target (Son & Thompson, 1995) . Schwann cells are vital for the process of axonal regeneration (Hall, 1986 (Hall, , 1997 , and one of their roles is as a source of neurotrophic factors (Heumann et al. 1987 ; Acheson et al. 1991 ; Sendtner et al. 1992) . These diffuse from the distal stump across the injury area to exert a trophic influence on the axons regenerating from the proximal stump (Reynolds & Woolf, 1993) . The contact with regenerating axons stimulates a second phase of Schwann cell proliferation, which is mediated by a neuronally derived trophic factor specific for glial cells. However, if axonal regeneration is delayed, Schwann cells decrease progressively in number and become less responsive to axonal regeneration (Li et al. 1997 ; Terenghi et al. 1998) .
In the proximal stump, the axons degenerate retrogradely as far as to the first node of Ranvier, creating a small area of wallerian degeneration. Within a few hours, the injured axons give rise to several neuronal sprouts (Wong & Mattox, 1991) , whose number is in excess of the number of axons originally in the nerve fascicles. It has been proposed that this phenomenon is to maximise the chances for each neuronal cell reaching its target organ. Some of these sprouts will ' die back ' through axonal pruning (Brushart, 1993) because of insufficient survival signal from the target organ, most probably in the form of growth factors. The terminal tip of the regrowing axons, or growth cone, responds to contact guidance cues and actively searches for a suitable matrix and environment to support the axonal growth (Bixby et al. 1988 ; Rutishauser, 1993) . Schwann cells from the distal stump are the most effective substrate to produce and direct regeneration (Bixby et al. 1988) , and successful axonal regeneration depends on the interaction between axons and glial cells (Hall, 1986 (Hall, , 1997 . Although the release and presence of growth factors play an important part in the regeneration process, an interaction between Schwann cell membrane and growth cone is mediated by cell adhesion molecules (CAMS) expressed by both elements (Rutishauser, 1993) . There is also evidence to suggest that nerve growth factor (NGF), and other growth factors, released by Schwann cells may potentiate axonal regeneration by upregulating neuronal CAMS expression (Friedlander et al. 1986 ; Seilheimer & Schachner, 1987) .
During regeneration, the axons also respond selectively to tropic cues (Gu et al. 1995) and grow back preferentially towards the target organ which they originally innervated, although the mechanism regulating this specificity is not fully understood. Motor fibres will seek out and selectively innervate a motor distal axonal stump (Brushart et al. 1987 ; Brushart, 1988 ; . This phenomenon is thought to depend on the preferential expression of the L2 epitope by the myelinating Schwann cells associated with motor axons (Martini et al. 1994) . The differential expression of this epitope on Schwann cells associated with sensory axons could provide a tropic cue for the motor axons to regenerate in the appropriate pathway. However, muscle sensory afferents retain a high degree of accuracy for reinnervation to the appropriate muscle (Madison et al. 1996) and sensory fibres reinnervate end organs of the same subtype originally innervated (Dykes, 1984) . This is consistent with clinical finding that different types of sensation (i.e. pressure, pain, temperature, etc.) are not confused after reinnervation (Dellon, 1981 ; Terzis & Smith 1990) . It would seem that sensory nerves lack topographic specificity (Rath et al. 1991 b) , but they display target organ specificity, derived from the presence of specific neurotrophic factors.
 
Cytokines and growth factors are a varied group of polypeptides produced by different cell types and showing overlapping actions (Hopkins & Rothwell, 1995 ; Rothwell & Hopkins, 1995) . Although the 2 terms are often used as synonyms, the major distinction between the 2 is that cytokines are inducible while growth factor are constitutive. However, both are upregulated and particularly active in highmetabolism situations, such as trauma and inflammation. Cytokines and growth factors have been subdivided into families according to their sequence similarity and to the type of binding receptors (Hokpkins & Rothwell, 1995) . Within the growth factor group, neurotrophic factors specifically influence neuronal activity by promoting development and maturation during embryonic life, and by sustaining maintenance during adult life and regeneration after injury. There are numerous neuronal growth factors, and it would be impossible to give here a comprehensive review. For this reason, this article will concentrate on the neurotrophins and on a few other growth factors, whose roles and actions have been shown to overlap and complement those of the neurotrophins in promoting peripheral neuron survival and regeneration.
The basic neurotrophic factor concept is defined by the hypothesis that trophic proteins are synthesised in the target tissues, and delivered to the neuronal soma via retrograde transport where they exert a trophic and survival effect (Purves, 1986 ; Oppenheim, 1991 ; Lindsay, 1996 a) . During fetal development, the supply of growth factors is limiting for neurons innervating various target tissues in order to select and sustain specific neuronal subpopulations, while the surplus neurons undergo cell death (Davies, 1996 ; Snider & Silos-Santiago, 1996) . The first neuronal growth factor to be discovered, and the prototype for the concept of neurotrophic factors, is NGF, which is specific for a subset of primary sensory neurons and for sympathetic neurons (Levi-Montalcini, 1987).
NGF is produced by the target organs (Bandtlow et al. 1987 ; Barde, 1990 Barde, , 1994 Anand et al. 1996) , from where it is delivered to the neuronal cell bodies by retrograde axonal transport (Di Stefano et al. 1992) following binding to specific receptors and internalisation by the nerve terminals (Thoenen & Barde, 1980 ; Lewin & Barde, 1996) . There is a wealth of information about the role and actions of NGF (see Rush et al. 1995 for review), which has also stimulated the research on other neurotrophic factors.
Other members of the neurotrophin family include brain derived neurotrophic factor (BDNF) (Barde et al. 1978) , neurotrophin-3 (NT-3) (Ernfors et al. 1990) and neurotrophin 4\5 (NT-4\5) (Berkemeier et al. 1991 ; Hallbook et al. 1991) . All these proteins have a high degree of amino acid homology with NGF (Glass & Yancopoulos, 1993 ; Maness et al. 1994) . They share a low-affinity receptor p75 (Chao et al. 1986) , to which they bind with equal affinity (Rodriguez-Tebar et al. 1990 . Although the specific role of p75 is not completely understood, this receptor interacts with high affinity receptors belonging to the tyrosine kinase (trk) receptor family (Barbacid, 1994 ; Chao & Hempstead, 1995) . Low and high affinity receptors are colocalised within the same neurons (Verge et al. 1992 ) and their interaction is crucial for the internalisation of neurotrophins within the neuronal terminals (Gargano et al. 1997) . Three trk receptors have been identified, each specific for a different neurotrophin : trkA is the signal transducing receptor for NGF (Kaplan et al. 1991) , trkB is specific for BDNF and NT-4\5 (Klein et al. 1989 (Klein et al. , 1992 , while NT-3 binds preferentially to trkC (Lamballe et al. 1991) . Cross-reactivity between NT-3 and other high affinity trk receptors has been reported, although the avidity of the binding and the potency of the neuronal response may be variable (Squinto et al. 1991 ; Davies et al. 1995 ; Ryde! n & Iba! n4 ez, 1996) .
All 3 trk receptors are distributed to discrete but partially overlapping subpopulations of primary sensory neurons, which give rise to different types of afferents and modulate specific sensory functions (McMahon et al. 1994 ; Wright & Snider, 1995 ; Bennett et al. 1996) , while trkB and trk C are also present in spinal motoneurons (Ernfors et al. 1993 ; Funakoshi et al. 1993) . Consistently, the target tissue innervated by the afferents of the different trk neurons express mRNA for the relevant neurotrophin (Davies et al. 1987 ; Maisonpierre et al. 1990 ; Ernfors et al. 1992 ; Buchman & Davies, 1993 ; Griesbeck et al. 1995) . Hence the growth factors are retrogradely transported from the peripheral target organs to the appropriate neuronal cells (Di Stefano et al. 1992 ).
Schwann cells in peripheral nerves also synthesise growth factors, and their synthesis is regulated by axonal contact or, in case of injury, loss of it (Reynolds & Woolf, 1993) .
Approximately a third of primary sensory neurons do not express trk receptors, and can be identified by the binding of the lectin IB4. These neurons have been found to express Ret mRNA, the signal transduction component of the receptor for glial-derived neurotrophic factor (GDNF), a member of the transforming growth factor-β (TGF-β) superfamily (Lin et al. 1993) . Ret is a common receptor for GDNF and neurturin, and it interacts with either of 2 other receptor subunits, GFRα-1 and GFRα-2 (Jing et al. 1996 ; Baloh et al. 1997) . Ret receptors have been identified in small diameter primary sensory neurons, and colocalise with GFRα-1 and GFRα-2 subunits (Bennett et al. 1998 ). GDNF has a trophic effect on dorsal root ganglion cells as well as on motoneurons and autonomic neurons (Henderson et al. 1994 ; BujBello et al. 1995 ; Matheson et al. 1997 ; Bennett et al. 1998) .
Ciliary neurotrophic factor (CNTF) is a neuroactive cytokine which overlaps considerably with neurotrophin in terms of neuronal specificity, although its cellular localisation, receptor structure and signalling pathway are distinct from those of the neurotrophin family (Ip & Yancopoulos 1992 ; Richardson, 1994) . CNTF is abundantly present in normal peripheral nerves, being localised mainly in the cytoplasm of myelinating Schwann cells (Friedman et al. 1992 ; Rende et al. 1992) . The mechanism of release of CNTF from the Schwann cells is still unclear as the protein lacks the signal sequence generally associated with secreted proteins (Stockli et al. 1989) . Its CNTFα receptor has been localised to muscle and spinal cord (Davis et al. 1991 ; Helgren et al. 1994 ) and consistently CNTF promotes survival of motoneurons in vitro and in neonatal animals following axotomy (Arakawa et al. 1990 ; Sendtner et al. 1990 ). Despite these survival-promoting effects, the role of CNTF in normal adult neuronal trophic support is still unresolved, and it has been speculated that CNTF may act as an ' injury factor ', being released by glial cells in response to injury (Adler, 1993) .
A newly discovered growth factor which has been linked to peripheral neuronal survival is leukaemia inhibitory factor (LIF) (Yamamori et al. 1989) . In vitro, the actions of LIF on sympathetic neurons are very similar to those of CNTF (Yamamori et al. 1989 ; Nawa et al. 1990 ). Like other neurotrophic factors, LIF is retrogradely transported by a subpopulation of small diameter neurons in dorsal root ganglia (DRG).
A large proportion of these neurons are also positive for trkA and CGRP, while the remaining are labelled by IB4 (Thompson et al. 1997 ). This overlap between neurons accumulating LIF and those responsive to NGF is much wider that that described for cells showing receptors for neurotrophin and GDNF (Michael et al. 1997 ; Bennett et al. 1998) . These findings and the demonstration that sympathetic neurons transport retrogradely both to NGF and NT-3 from peripheral target tissues ) are consistent with the intriguing possibility that there may be multiple growth factor control on neuronal functions and survival.
Glial growth factor (GGF) is a trophic factor specific for Schwann cells rather than neurons, but it has a significant role in the interaction of the 2 cell types. GGF was originally characterised as a Schwann cell mitogen, and only subsequently it was found to be part of a family of proteins known as neuregulins, encoded in a single gene and differentially spliced during transcription (Marchionni et al. 1993 ). The neuregulin proteins acts via heterodimers of erbB2, erbB3 and erbB4 receptors (Carraway & Burden, 1995) which are also present on glial cells. Neuregulin mRNA is expressed by primary sensory neurons, motoneurons and sympathetic neurons (Marchionni et al. 1993 ; Chen et al. 1994) . During development, GGF is trophic for Schwann cell precursors and stimulates cell proliferation (Dong et al. 1995) and is critical for the survival of Schwann cells in developing neuromuscular junctions (Tranchtenberg & Thompson, 1996) . In adults, GGF increases Schwann cell motility and proliferation, the 2 effects being dependent on the concentration of growth factor available to the glial cells (Mahanthappa et al. 1996) . Hence GGF may promote neuronal survival and proliferation indirectly, by promoting glial cellsneuron interaction (Reynolds & Woolf, 1993) .
It is clear that trophic factors play an important role during development as well as in adult life. It has been found that some neuronal populations may be sustained during development by a specific trophic factor, but they switch to a different trophic support in adult life as shown by the changing pattern of expression of different neurotrophins (Maisonpierre et al. 1990 ; Zhang et al. 1994 ; Oakley et al. 1995 ; Verdi et al. 1996 ; Belliveau et al. 1997 ; Rush et al. 1997) . Similarly, the IB4-labelling subpopulation of primary sensory neurons start to express the Ret receptor for GDNF perinatally, after the downregulation of NGF-binding trkA which is prevalent in these cells during fetal development. In adult life, IB4-labelled cells do not express trk receptors and are totally dependent on GDNF trophic support (Molliver et al. 1997) . In adults, peripheral nerve injury seems to recapitulate, at least partially, the events which occur during development, with regulatory changes of trophic factors and their receptors.
      

Primary sensory neurons
In adults, peripheral nerve injury is followed by significant neuronal cell death in the DRG, with 20-40 % of neurons within the DRG being lost (Ardvidsson et al. 1986 ; Schmalbruch, 1987 ; Himes & Tessler, 1989 ; Liss et al. 1994 ), most probably due to apoptosis (Edstro$ m et al. 1996 ; Groves et al. 1997 ).
There is also downregulation of trk receptor expression in response to a peripheral nerve lesion and to availability of neurotrophic factors (Ernfors et al. 1993 ; Krekowski et al. 1996) . These changes are counteracted by the exogenous administration of neurotrophins (Verge et al. 1996) , which can also improve the physiological activity of the sensory neurons .
Following axonal injury, Schwann cells of the distal stump upregulate the synthesis of NGF, BDNF, NT-4 and p75, but not NT-3 (Heumann et al. 1987 ; Meyer et al. 1992 ; Funakoshi et al. 1993 ; Anand et al. 1997) . The increase of the low-affinity receptors is detectable before axonal degeneration (Robertson et al. 1995) and it is thought that the combined NGF and p75 increase may promote the proliferation and migration of Schwann cells (Anton et al. 1994) . However, the neurotrophin levels made available at the site of injury are not sufficient to compensate for the lack of target derived neurotrophic factor to maintain cell survival (Johnson et al. 1985 ; Heumann et al. 1987) . In those neurons which survive the initial insult, the regenerative response is accompanied by a shift in synthesis of mRNA, which is best characterised by the modification in phenotypic neuropeptide expression in primary sensory neurons. There is a downregulation of calcitonin gene related peptide (CGRP) and substance P (SP), whose expression in small and medium size sensory neurons is regulated by NGF (Lindsay & Harmar, 1989) . Changes of retrogradely transported signal not linked to NGF also cause upregulation of vasoactive intestinal peptide (VIP), neuropeptide Y (NPY) and galanin in well defined neuronal subpopulations (Kashiba et al. 1992 ; Ho$ kfelt et al. 1994 ; Zhang et al. 1995 ; Wakisaka et al. 1996) . The link between trophic factors and peptide phenotypic expression has been used as a marker of neuronal injury and of the response of subpopulations of DRG neurons to trophic factors. Evidence from in vitro studies support the contention that neuropeptide alterations are regulated by neurotrophic factors (Lindsay & Harmar ; Mulderry, 1994 ; Kerekes et al. 1997) . Consistently, in vivo administration of NGF reverses the decrease of CGRP and SP expression in small diameter primary sensory neurons due to nerve injury (Fitzgerald et al. 1985 ; Wong & Oblinger, 1991 ; Verge et al. 1995) , while GDNF acts on somatostatin expression in small size neurons which are not responsive to NGF (Bennett et al. 1998) . Also, administration of NT-3 downregulates NPY immunostaining in large diameter sensory neurons (O'Hara et al. 1995 ; Verge et al. 1996 ; Sterne et al. 1998) , and LIF influences the expression of galanin on small diameter neurons (Corness et al. 1996 ; Thompson et al. 1998 ).
At present, there is no recognised role for BDNF regulation of expression on any known peptide or neuronal marker. BDNF is synthesised in adult primary sensory neurons (Ernfors et al. 1990 ; Cho et al. 1997) , and a generalised autocrine role of BDNF on sensory neurons has been suggested following in vitro experiments (Achenson et al. 1995) . However, in vivo BDNF mRNA is mainly expressed in trkA neurons (Kashiba et al. 1997 ) and only occasionally in trkB cells, which would not support an autocrine role for this neurotrophin (Michael et al. 1997) . Recently, it has been shown that NGF increases BDNF synthesis in almost 90 % trkA-expressing DRG cells (Cho et al. 1997 ; Michael et al. 1997) . Similarly a BDNF increase is found in many trkA DRG neurons following peripheral inflammation (Cho et al. 1997 ), possibly as a response to peripheral NGF, which acts as mediator in inflammation and pain processing (McMahon et al. 1995 ; McMahon, 1996 ; Woolf 1996) . BDNF is transported axonally to the central and peripheral processes of the trkA neurons (Zhou & Rush, 1996 ; Michael et al. 1997) , where it is found in dense-cored vesicles (Michael et al. 1997) . Axotomy increases the synthesis and anterograde transport of BDNF from sensory neurons (James et al. 1998 ) and it has been postulated that it might act as an anterograde trophic messenger, being released in the dorsal horn under the influence of NGF and modulating nociceptive signalling (Michael et al. 1997 ). However, a small percentage of trkC neurons and some IB4 labelled small cells also express BDNF mRNA, and NGF treatment does not have any effect on BDNF synthesis in these cells (Michael et al. 1997) , which leaves the question of BDNF role in DRG still open.
Following nerve axotomy, GGF mRNA increases rapidly in dorsal root ganglia neurons, coinciding with the beginning of Schwann cell proliferation in the distal nerve stump (Li et al. 1997) . Expression of erbB2 and erbB3 receptors on distal nerve stump glial cells is also upregulated initially after injury (Li et al. 1997) , and this increase persists in response to GGF, indicating a coordinated response to axotomy between axon and Schwann cells (Carroll et al. 1997) . Another example of this interrelationship is the rapid apoptotic death of Schwann cells at neuromuscular junctions following axotomy, which is prevented by injection of GGF (Trachtenberg et al. 1996) .
Motoneurons
Nerve axotomy produces a progressive loss of choline acetyltransferase and increased expression of trkB and p75 in motoneurons (Friedman et al. 1995) , although the upregulation of p75 has been related to axonal regeneration rather than to a signal of nerve damage (Rende et al. 1993) . The changes are particularly evident in brainstem motoneurons, compared with spinal motoneurons (Rende et al. 1997) , possibly due to the different responsiveness of the motoneurons to different growth factors released peripherally.
BDNF has been shown to reduce motoneuron death after axotomy in neonatal animals (Yan et al. 1992 ) and in adults after ventral root avulsion (Novikov et al. 1995 ; Novikova et al. 1997) . Intrathecal administration of BDNF reverses both soma atrophy and reduction of choline acetyl transferase in motoneurons (Kishino et al. 1997) . Similar beneficial effects were also observed after BDNF administration to the axotomised hypoglossal ) and sciatic (Friedman et al. 1995) nerves, although the effect of BDNF appears to be dose dependent (Vejsada et al. 1994 (Vejsada et al. ,1995 .
CNTF has a potent trophic role on motoneurons during development and postnatally (Sendtner et al. 1990 ; Richardson, 1994) and recently a direct effect of CNTF has also been shown on adult motoneuron survival in vivo (Sendtner et al. 1997) . Following nerve injury, CNTF in Schwann cells of the distal stump is reduced considerably, this reduction extending to the neuromuscular junction (Hiruma et al. 1997 ). This deficit might explain the beneficial effect of CNTF administration on target organ motor reinnervation. Indeed, systemic CNTF administration enhances muscle fibre reinnervation and intramuscular nerve branching (Ulenkate et al. 1994) , while promoting the preservation of muscle mass (Newman et al. 1996) . CNTF also stimulates increased myelination of regenerating axons (Sahenk et al. 1994 ), but without any significant effect on the regeneration of proximal axons (Ulenkate et al. 1994) .
As CNTF and LIF utilise common signalling pathways (Ip et al. 1992 ) and have overlapping actions on peripheral neurons, it has been suggested they may have a common mechanism of action. Both CNTF and LIF show increased peripheral retrograde transport after nerve injury (Curtis et al. 1993 (Curtis et al. , 1994 . The fact that LIF mRNA is increased in peripheral nerve after axotomy and that it is not readily taken up by intramuscular terminals (Curtis et al. 1994 ) has led to the suggestion that the source of LIF may not be the target muscle but Schwann cells, as for CNTF. Indeed, an upregulation of LIF mRNA can be induced in cultured Schwann cells (Matsuoka et al. 1997) , and LIF administration to the axotomised nerve enhances nerve regeneration and myelination, while also increasing muscle mass and muscle contraction force (Tham et al. 1997 ) Consistently in LIF knockout mice, muscle regeneration is significantly reduced, but counteracted by LIF infusion (Kurek et al. 1997) .
NT-3 mRNA is present in significant amounts in adult skeletal muscle (Griesbeck et al. 1995) , exerting a trophic role for sensory neurons innervating muscle spindles and for motoneurons (Ernfors et al. 1994 ; Tessarolo et al. 1994) . The strong trophic effect on muscle sensory afferents is evident following exogenous administration of NT-3, even in the absence of the target organ (Oakley et al. 1997) . The data from NT-3 knock-out mouse studies have also shown that NT-3 is trophic for proprioceptive and mechanoreceptive sensory neurons (Ernfors et al. 1994 ; Airaksinen et al. 1996) . Consistently, NT-3 containing neurons are mainly localised in trigeminal, cervical and lumbar spinal ganglia (Zhou & Rush, 1995) and in vitro NT-3 promotes neurite outgrowth from DRGs which innervate limb muscles (Hory- Lee et al. 1993) . The trophic action of NT-3 on motoneurons is confirmed by the enhanced neurite outgrowth from spinal cord explants as well as by the increased number of motor end-plates formed in cocultures of neurons and muscle (Braun et al. 1996) . Furthermore, the exogenous administration of NT-3 restores muscle mass and it is selectively beneficial for the reinnervation of type 2b fast muscle fibres (Sterne et al. 1997 b) , suggesting that different growth factors might sustain preferentially different type of motoneurons, as classified by the phenotype they confer to muscle fibres.
Evidence that GDNF mRNA expression is regulated in skeletal muscle (Henderson et al. 1994 ) and that it is transported retrogradely to motoneurons (Yan et al. 1995) are strong indications of its physiological role for motoneurons. GDNF is a potent survival factor for motoneurons in vitro and in vivo (Henderson et al. 1994 ; Yan et al. 1995) . Following ventral root avulsion in adults, GDNF administration prevents motoneuron cell death (Li et al. 1995) and shows a long-term effect in reducing axotomy-induced soma atrophy (Matheson et al. 1997 ). In addition, in adult motoneurons GDNF prevents the axotomy-induced ChAT immunoreactivity decrease (Henderson et al. 1994 ; Yan et al. 1995) . Overexpression of muscle GDNF by transgenic mice increases the number of motor axons innervating the neuromuscular junction in a dose-related manner (Nguyen et al. 1998) , although overexpression of GDNF by glial cells or of NT-3 and NT-4 by muscle does not have the same effect. The differential effect of glial and muscle-derived GDNF and the identification of 2 alternatively spliced forms of GDNF from muscle and Schwann cells (Springer et al. 1995 ) raises the intriguing possibility that both the type of growth factor and the site of synthesis might lead to specific and well defined effects on the recipient neurons. This might be due to the differential availability of the trophic factor and its receptors. For example, in normal adult mice GDNF and GFRα-1 mRNAs are expressed at detectable levels in peripheral nerve, while expression of Ret mRNA is found in spinal motoneurons but not peripherally. After sciatic nerve crush, there is a rapid upregulation of GDNF and GFRα-1 synthesis in distal nerve, with a delayed GDNF mRNA increase in the muscle. This coincides with a rapid increase of Ret mRNA expression in motoneurons and DRG (Naveilhan et al. 1997) . Hence, following nerve injury, the mode and site of administration of a trophic factor would be crucial to a resulting beneficial effect.
   
Following peripheral nerve injury and axotomy, there is a disruption in the supply of retrogradely transported neurotrophic factors, leading to neuronal cell death and lack of regeneration. This process can be reversed if the neurons regenerate back to peripheral targets, indicating the dependence on target-derived neurotrophic factors (Mendell, 1996) . Hence it seems feasible that the addition of exogenous trophic factors to the microenvironment of the injured nerve might produce results similar to those of target organ reinnervation.
Immediately after a nerve lesion, there is a decrease of trkA and p75 expression in DRG (Krekoski et al. 1996) . The ability of NGF to regulate differentially the neuropeptide expression in sensory neurons is paralleled by its capacity in counteracting the effect of nerve injury on the trkA-expressing DRG cells (Verge et al. 1996) . Consistently, administration of exogenous NGF has resulted in sustained axonal regeneration (Lindsay 1988 ; Hollowell et al. 1990 ; Chongliang et al. 1992 ; Derby et al. 1993 ; Whitworth et al. 1995 Whitworth et al. , 1996 , which has been related to a reduction in the incidence of neuronal cell death (Rich et al. 1989 b) . Exogenous NGF enhances regeneration of trkA expressing neurons, but also promotes the regeneration of large myelinated fibres and motor axons, which normally do not express trkA (Chongliang et al. 1992) , leading to the suggestion that NGF might be a general promoter of nerve regeneration. Also, it has been shown that continuous intrathecal infusion of NGF may actually delay the onset of regeneration, without compromising the rate of regeneration (Gold, 1997), possibly indicating that the initial loss of NGF following injury might act as signal for the onset of nerve regeneration. While exogenous NGF may facilitate regeneration, the availability of endogenous NGF appears to be essential for collateral sprouting of cutaneous sensory nerves (Diamond et al. 1992 a) . However, neutralisation of endogenous NGF with specific antibodies does not prevent axonal regeneration (Rich et al. 1984 ; Diamond et al. 1992 b) , showing a considerable difference in the biological response of the peripheral nervous system to contrasting growth stimuli.
Intrathecal administration of NT-3 contributes to the recovery of its specific receptor trkC and of p75 expression in DRG (Verge et al. 1996) . Furthermore, delivery to the axotomised nerve decreases the upregulation of NPY-immunoreactive cells in DRG which is seen after axotomy (O'Hara et al. 1995 ; Verge et al. 1996 ; Sterne et al. 1998 ). NT-3 stimulates neurite outgrowth from the stumps of cultured adult DRG (Edstro$ m et al. 1996) and in vivo targeted administration of NT-3 to the cut sciatic nerve using fibronectin mats improves the rate and amount of axonal regeneration . Following axotomy, continuous infusion of NT-3 has proved to be effective in restoring sensory and motor conduction velocity in dose-dependent manner , consistently with the neuroprotective role of NT-3 in sensory neuropathy (Gao et al. 1995 ; Helgren et al. 1997) . It is noteworthy that the concentration of NT-3 which shows a beneficial effect on nerve regeneration is much higher than that required for NGF-enhanced regeneration . Axonal regeneration appears to respond quickly to NGF administration (Whitworth et al. 1996) , while there is some delay between administration and evidence of an NT-3 effect on nerve regeneration This may be due to slower retrograde axonal transport in large-size sensory neurons compared with small ones (Grant et al. 1979) and to the differential rate of retrograde neurotrophin transport (DiStefano et al. 1992) . Also NT-3 appears to promote the regeneration of various subpopulations of DRG neurons , possibly due to NT-3 cross-reactivity with trkA and trkB receptors (Squinto et al. 1991 ; Davies et al. 1995 ; Ryde! n & Iba! n4 ez, 1996) .
BDNF administration by osmotic pump after sciatic nerve transection produces an improvement in diameter and myelin thickness in regenerating axons in the long term, an effect which is enhanced by combined administration with CNTF (Lewin et al. 1997) . Exogenous BDNF administration has also been shown to improve functional recovery following sciatic nerve transection (Lewin et al. 1997) , particularly when it is administered directly to the cut nerve (Utley et al. 1996) . Similarly, CNTF uptake and retrograde transport to DRG is more rapid following direct injection at the nerve injury site (Curtis et al. 1993) . CNTF in peripheral nerve is localised to Schwann cells, and its synthesis is decreased during wallerian degeneration (Friedman et al. 1992 ). This decrease extends to Schwann cells of intramuscular nerves and neuromuscular junctions (Hiruma et al. 1997) , it is very rapid and it is maintained for over 6 mo in cases of chronic denervation (Anand et al. 1997) . Nerve regeneration is accompanied by an increase of CNTF, which is indicative that axonal contact with glial cells is crucial to the maintenance of CNTF levels (Friedman et al. 1992 ; Anand et al. 1997) . This is consistent with the experimental findings in mice which exhibit delayed wallerian degeneration, where the expected decrease of CNTF is also delayed for many days (Subang et al. 1997) .
Evidence that GDNF might directly affect the peripheral nerve regeneration process are still forthcoming. GDNF has a beneficial effect on axonal regeneration as assessed by the nerve pinch test (Naveilhan et al. 1997 ) and intrathecal administration of GDNF reverses the decrease in IB4 labelling found in dorsal root ganglia after axotomy (Molliver et al. 1997 ; Bennett et al. 1998) . GDNF also improves the conduction velocity of motoneurons following regeneration , and that of small diameter sensory neurons (Bennett et al. 1998).
Despite the beneficial effect of GGF on Schwann cell motility and proliferation, as yet there are no data showing whether these effects may indirectly benefit axonal regeneration. However, the expression of cerbB receptors on Schwann cells in denervated distal stump is rapidly upregulated and is correlated with the increased expression of GGF in response to axotomy (Carroll et al. 1997 ; Li et al. 1997 ). In the long-term, there is a time-related downregulation of both c-erbB and p75 receptors on Schwann cells if axonal regeneration is prevented, although GGF synthesis is maintained (Li et al. 1997 ; You et al. 1997) . These results underline the axonal-glial interdependence after nerve injury, as the persistence of responsive Schwann cells in the distal stump is dependent on axonally derived trophic signalling, and in turn the responsive Schwann cells provide trophic support for the regrowing axons.
Although several experiments have demonstrated the usefulness of specific trophic factors in nerve regeneration, it is becoming more apparent that the survival of primary sensory neurons and motoneurons depends on multiple neurotrophic factors acting synergistically or in a well defined sequence. For example, NT-3 and BDNF have opposing regulatory roles on cortical dendritic cells (McAllister et al. 1997) and although such an effect has not been demonstrated for neurons projecting peripherally, it is conceivable that similarity might also be found in the peripheral nervous system. In culture of spiral ganglion cells, the effect of NT-3 is enhanced by LIF administration (Mazzarella et al. 1997) . In vitro evidence have also shown that GDNF from Schwann cells and muscle-derived cardiotrophin (CT-1) have a synergistic effect on motoneuron survival. In vivo motoneurons coexpress the receptor for both trophic factors, indicating that an integration of the signal from these 2 factors is essential for motoneuron survival (Arce et al. 1998 ).
   
Neurotrophic factors have been advocated as ideally suited for the treatment of neurodegenerative diseases of the CNS, neuropathies and peripheral nerve injury (Anand, 1996 ; Lindsay, 1996 b) . Many experiments outlined above have made use of miniosmotic pumps for intrathecal delivery of growth factors, in order to maintain a suitable supply for a sufficient length of time. However, this delivery system may not be generally suited for clinical application, and other ways of delivery have been investigated, including systemic delivery by subcutaneous or intraperitoneal injection, and targeted administration to the cut nerve using bioresorbable materials (i.e. fibronectin mats or collagen).
Direct administration of growth factors might be problematic when applied to patients, particularly when a continuous infusion of the molecule is required. It is likely that in future treatment strategies will be based on the transfer of genes, molecules or cells into the nervous system. New molecular biology techniques allow the insertion of specific genes into nondividing neuronal cells, which would then produce their own ' trophic support ' molecule (Hoffer & Olson, 1997) . Alternatively, regeneration of neurons may be prompted and sustained by grafts of cells which have been genetically manipulated to produce growth factor(s). Recently, genetically modified fibroblasts encapsulated in porous membrane have been shown to be an efficient way of delivering CNTF in a primate model of Huntington's disease (Emerich et al. 1997) . A similar approach has also been used to deliver NGF and BDNF (Emerich et al. 1994 ; Tuszynski et al. 1994 Tuszynski et al. , 1996 Kim et al. 1996) and it is conceivable that it would also be applicable to peripheral nerve injury. Growth factor cDNA can also be spliced into defective viruses which act as vectors. Herpes simplex virus expressing NGF can be injected directly into the nerve and transported retrogradely to mimic the physiological role of the neurotrophin. This method has been shown to prevent the decrease of TH activity seen in sympathetic ganglia after axotomy (Federoff et al. 1992) . Similarly, administration of CNTF and BDNF transduced in adenoviruses promotes the survival of neonatally axotomised motoneurons (Gravel et al. 1997) . Although these experimental strategies are still in the early stages of development, they show the potential of genetic manipulation for therapeutic application in the peripheral and central nervous system. Furthermore, these experiments demonstrate the possibility of modifying neuronal physiology in vivo by augmenting the expression and delivery of a critical gene product to neural cells when extra requirements for growth factors are needed. 
